Subscribe To
BIIB / Lecanemab And Biogen's Path To Growth
BIIB News
By Zacks Investment Research
October 30, 2023
Biogen Inc. (BIIB) Rises But Trails Market: What Investors Should Know
The latest trading day saw Biogen Inc. (BIIB) settling at $237.30, representing a +1.19% change from its previous close. more_horizontal
By Barrons
October 26, 2023
Biogen and Eisai's Revised Alzheimer's Drug Works, but Safety Questions Linger
Wall Street analysts say Biogen and Eisai could secure Food and Drug Administration approval for their injected Alzheimer's drug. more_horizontal
By Market Watch
October 25, 2023
Biogen and Eisai release new Alzheimer's drug data that may support wider uptake
Biogen Inc. and Eisai Co. late Wednesday released new data on their Alzheimer's treatment Leqembi that may ultimately help bolster uptake of the drug. more_horizontal
By Zacks Investment Research
October 23, 2023
Here's Why Biogen Inc. (BIIB) Fell More Than Broader Market
The latest trading day saw Biogen Inc. (BIIB) settling at $253.39, representing a -1.58% change from its previous close. more_horizontal
By Reuters
October 23, 2023
Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug
Swiss pharmaceutical company Roche has settled a patent lawsuit against U.S. biotech firm Biogen over its biosimilar version of Roche's blockbuster rh more_horizontal
By GlobeNewsWire
October 19, 2023
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting
CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new data from its Alzheimer's disease portfolio at the upc more_horizontal
By Zacks Investment Research
October 17, 2023
Biogen Inc. (BIIB) Falls More Steeply Than Broader Market: What Investors Need to Know
In the closing of the recent trading day, Biogen Inc. (BIIB) stood at $267.43, denoting a -0.19% change from the preceding trading day. more_horizontal
By CNBC Television
October 11, 2023
Final Trades: WST, BIIB, SPY & MDT
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders. more_horizontal